Back to Stocks

VYGR

Voyager Therapeutics, Inc.
6 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Voyager Therapeutics is successfully transitioning from a broad-spectrum biotech into a lean, high-conviction enterprise focused on neurological breakthroughs.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a lean transition, Voyager's financial health reveals growing vulnerabilities. Collaboration revenue plummeted 59% year-over-year to $2.6 million, signaling a loss of momentum in the company's primary non-dilutive funding streams.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every VYGR filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a critical crossroads, balancing aggressive cost-cutting against the inherent volatility of early-stage drug development. Voyager has successfully reduced its burn rate and narrowed its losses, but the precipitous drop in collaboration revenue suggests that the 'platform' story may be struggling to generate consistent cash flow. The tension between the reported $171.7 million liquidity and the looming lease and severance obligations suggests a tighter financial window than management's optimistic guidance implies. Ultimately, the stock's trajectory will be determined by the second half of 2026. The convergence of the VY1706 IND process and the VY7523 imaging data will either validate the TRACER capsid platform and the company's strategic pivot or expose the fragility of its capital structure. Investors are essentially betting on a binary clinical window, where the reward is a validated CNS leader and the risk is a capital-starved biotech with a shrinking revenue base.

Selected Quarter

Core Takeaway

Voyager is trading broad pipeline diversity for clinical focus and cost efficiency, betting the company on H2 2026 data.

Investor Lens

The trade-off is between a disciplined, focused execution plan and the risk of a liquidity crunch if clinical milestones are missed.

Watch Next

IND clearance and first-in-human dosing for VY1706 in the second half of 2026.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.07Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bullishMay 7

Operating expenses decreased 20% YoY due to portfolio prioritization and cost-cutting.

margin expansion
60%
bearishMay 7

Collaboration revenue plummeted 59% year-over-year.

earnings miss
80%
neutralMay 7

Raised $3.0 million through ATM facility in Q1 2026.

capital raise
40%
bullishMay 7

Discontinued the SOD1 program to reduce R&D spend and focus resources.

divestiture
50%
bullishMay 7

Operating expenses decreased 20% YoY due to portfolio prioritization and cost-cutting.

margin expansion
60%
bearishMay 7

Collaboration revenue plummeted 59% year-over-year.

earnings miss
80%
neutralMay 7

Raised $3.0 million through ATM facility in Q1 2026.

capital raise
40%
bullishMay 7

Discontinued the SOD1 program to reduce R&D spend and focus resources.

divestiture
50%
bullishMay 7

Operating expenses decreased 20% YoY due to portfolio prioritization and cost-cutting.

margin expansion
60%
bearishMay 7

Collaboration revenue plummeted 59% year-over-year.

earnings miss
80%
neutralMay 7

Raised $3.0 million through ATM facility in Q1 2026.

capital raise
40%
bullishMay 7

Discontinued the SOD1 program to reduce R&D spend and focus resources.

divestiture
50%
bullishMay 7

Operating expenses decreased 20% YoY due to portfolio prioritization and cost-cutting.

margin expansion
60%
bearishMay 7

Collaboration revenue plummeted 59% year-over-year.

earnings miss
80%
neutralMay 7

Raised $3.0 million through ATM facility in Q1 2026.

capital raise
40%
bullishMay 7

Discontinued the SOD1 program to reduce R&D spend and focus resources.

divestiture
50%
bullishMay 7

Operating expenses decreased 20% YoY due to portfolio prioritization and cost-cutting.

margin expansion
60%
bearishMay 7

Collaboration revenue plummeted 59% year-over-year.

earnings miss
80%
neutralMay 7

Raised $3.0 million through ATM facility in Q1 2026.

capital raise
40%
bullishMay 7

Discontinued the SOD1 program to reduce R&D spend and focus resources.

divestiture
50%
bullishMay 7

Operating expenses decreased 20% YoY due to portfolio prioritization and cost-cutting.

margin expansion
60%
bearishMay 7

Collaboration revenue plummeted 59% year-over-year.

earnings miss
80%
neutralMay 7

Raised $3.0 million through ATM facility in Q1 2026.

capital raise
40%
bullishMay 7

Discontinued the SOD1 program to reduce R&D spend and focus resources.

divestiture
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a company at a critical crossroads, balancing aggressive cost-cutting against the inherent volatility of early-stage drug development. Voyager has successfully reduced its burn rate and narrowed its losses, but the precipitous drop in collaboration revenue suggests that the 'platform' story may be struggling to generate consistent cash flow. The tension between the reported $171.7 million liquidity and the looming lease and severance obligations suggests a tighter financial window than management's optimistic guidance implies. Ultimately, the stock's trajectory will be determined by the second half of 2026. The convergence of the VY1706 IND process and the VY7523 imaging data will either validate the TRACER capsid platform and the company's strategic pivot or expose the fragility of its capital structure. Investors are essentially betting on a binary clinical window, where the reward is a validated CNS leader and the risk is a capital-starved biotech with a shrinking revenue base.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.